Clinical trials
Kidney Failure, Chronic trials in Austria
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 2 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 1 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
| Recruiting | 3 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
| Enrolling by invitation | 1 |
| Terminated | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Medical University of Vienna | 4 |
| Heidelberg University | 3 |
| Medical University of Graz | 2 |
| Novartis Pharmaceuticals | 2 |
| Prim. Priv. Doz. Dr. Daniel Cejka | 2 |
| Amgen | 1 |
| Bayer | 1 |
| Bioverativ, a Sanofi company | 1 |
| Bristol-Myers Squibb | 1 |
| C. R. Bard | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Kidney Failure, Chronic | 31 |
| Renal Insufficiency, Chronic | 8 |
| Cardiovascular Diseases | 3 |
| Kidney Diseases | 3 |
| Renal Insufficiency | 3 |
| Atherosclerosis | 2 |
| Coronary Artery Disease | 2 |
| Diabetes Mellitus | 2 |
| Heart Diseases | 2 |
| Peripheral Arterial Disease | 2 |
Trials
Showing 26 to 31 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.